The Age of the Wildfire - References

July 15, 2005

13 Min Read
SupplySide Supplement Journal logo in a gray background | SupplySide Supplement Journal


Aug. 15, 2005 - Natural Products Industry INSIDER
"Age of the Wildfire" (Inflammation story) References

1. Zhao G et al. Dietary alpha-linolenic acid reduces inflammatory andlipid cardiovascular risk factors in hypercholesterolemic men and women. JNutr. 134, 11:2991-97, 2004. www.nutrition.org

2. Mori TA, Beilin LJ. "Omega-3 fatty acids and inflammation." CurrAtheroscler Rep. 6, 6:461-7, 2004.

3. Ciubotaru I, Lee YS, Wander RC. "Dietary fish oil decreasesC-reactive protein, interleukin-6 and triacylglycerol to HDL-cholesterol ratioin postmenopausal women on HRT." J Nutr Biochem. 14, 9:513-21, 2003.www.elsevier.com/locate/jnutbio

4. Leiba A et al. Diet and lupus. Lupus. 10, 3:246-8, 2001.

5. Das UN. Hypothesis: can glucose-insulin-potassium regimen incombination with polyunsaturated fatty acids suppress lupus and otherinflammatory conditions? Prostagland Leukotr Essent Fatty Acids. 65,2:109-13, 2001. www.harcourt-international.com/journals/plef

6. Das UN. Long-chain polyunsaturated fatty acids interact with nitricoxide, superoxide anion, and transforming growth factor-beta to prevent humanessential hypertension. Eur J Clin Nutr. 5, 2:195-203, 2004. http://www.nature.com/ejcn/index.html

7. James MJ et al. Dietary n-3 fats as adjunctive therapy in a prototypicinflammatory disease: issues and obstacles for use in rheumatoid arthritis. ProstaglandLeukotr Essent Fatty Acids. 68, 6:399-405, 2003. www.harcourt-international.com/journals/plef

8. Mayser p et al. Omega-3 fatty acid-based lipid infusion in patientswith chronic plaque psoriasis: results of a double-blind, randomized,placebo-controlled, multicenter trial. J Acad Dermatol. 38, 4:539-47,1998.

9. Stene LC et al. Use of cod liver oil during the first year of life isassociated with lower risk of childhood-onset type 1 diabetes: a large,population-based, case-control study. Am J Clin Nutr. 78, 6:1128-34,2003. www.ajcn.org

10. SanGiovanni JP, Chew EY. "The role of omega-3 long-chainpolyunsaturated fatty acids in health and disease of the retina." ProgRetin Eye Res. 24, 1:87-138, 2005.

11. Desmettre T, Rouland JF. "[Hypothesis on the role of nutritionalfactors in ocular hypertension and glaucoma.]" J Fr Ophthalmol. 28,3:312-6, 2005.

12. Xi ZP, Wang JY. "Effect of dietary n-3 fatty acids on thecomposition of long- and very-long-chain polyenoic fatty acid in ratretina." J Nutr Sci Vitaminol (Tokyo). 49, 3:210-3, 2003.

13. Elner VM. "Retinal pigment epithelial acid lipase activity andlipoprotein receptors: effects of dietary omega-3 fatty acids." Trans AmOphthalmol Soc. 100:301-38, 2002.

14. Hardman WE. (n-3) fatty acids and cancer therapy. J Nutr. 134,12:3427S-30S, 2004. www.nutrition.org

15. Trebble TM et al. Fish oil and antioxidants alter the composition andfunction of circulating mononuclear cells in Crohn disease. Am J Clin Nutr.80, 5:1137-44, 2004. www.ajcn.org

16. Jolly CA and Fernandes G. Diet modulates Th-1 and Th-2 cytokineproduction in the peripheral blood of lupus-prone mice. J Clin Immunol.19, 3:172-8, 1999. www.kluweronline.com/issn/0271-9142/current

17. Halpern GM. Anti-inflammatory effects of a stabilized lipid extract ofPerna canaliculus, Lyprinol. Allerg Immunol. 32, 7:272-8, 2000.

18. DeLuca P et al. Effects of gamma-linolenic acid on interleukin-1 betaand tumor necrosis factor-alpha secretion by stimulated human peripheral bloodmonocytes: studies in vitro and in vivo. J Investig Med. 47, 5:246-50,1999.

19. Laposata m et al. Alteration of the cellular fatty acid profile andthe production of eicosanoids in human monocytes by gamma-linolenic acid. ArthritisRheumatism. 33, 10:1526-33, 1990. http://www3.interscience.wiley.com/cgi-bin/currentissue?ID=7650974

20. Watson J et al. Cytokine and prostaglandin production by monocytes ofvolunteers and rheumatoid arthritis patients treated with dietary supplements ofblackcurrant seed oil. Br J Rheumatol. 32, 12:1055-8, 1993.

21. Oz HS et al. "Antioxidants as novel therapy in a murine model ofcolitis." J Nutr Biochem. 16, 5:297-304, 2005. www.elsevier.com/locate/jnutbio

22. Smith GV, Farthing MJ. "The effect of ascorbic acid on Helicobacterpylori-induced cyclooxygenase 2 expression and prostaglandin E2 production bygastric epithelial cells in vitro." Helicobacter. 10, 1:83-9, 2005.

23. Smith GV, Farthing MJ. "The effect of ascorbic acid on Helicobacterpylori-induced cyclooxygenase 2 expression and prostaglandin E2 production bygastric epithelial cells in vitro." Helicobacter. 10, 1:83-9, 2005.

24. Korantzopoulos P et al. Oral vitamin C administration reduces earlyrecurrence rates after electrical cardioversion of persistent atrialfibrillation and attenuates associated inflammation. Int J Cardiol.102, 2:321-6, 2005. http://www.sciencedirect.com/science/journal/01675273

25. Mayland CR et al. Vitamin C deficiency in cancer patients. PalliatMed. 19, 1:17-20, 2005 . http://www.ingentaconnect.com/content/arn/pm

26. Kluft C et al. Serum carotenoids and vitamins in relation to markersof endothelial function and inflammation. Eur J Epidemiol. 19,10:915-21, 2004.

27. Lee SJ et al. Astaxanthin inhibits nitric oxide production andinflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaBactivation. Mol Cells. 16, 1:97-105, 2003. www.molcells.org

28. Bennedsen M et al. "Treatment of H. pylori infected mice withantioxidant astaxanthin reduces gastric inflammation, bacterial load andmodulates cytokine release by splenocytes." Immunol Lett. 70,3:185-9, 1999

29. Lee EH et al. Dietary lutein reduces ultraviolet radiation-inducedinflammation and immunosuppression. J Invest Dermatol. 122, 2:510-7,2004. http://www.blackwell-synergy.com/loi/jid

30. Gonzalez S et al. Dietary lutein/zeaxanthin decreases ultravioletB-induced epidermal hyperproliferation and acute inflammation in hairless mice.J Invest Dermatol. 121, 2:399-405, 2003. http://www.blackwell-synergy.com/loi/jid

31. Jesudason EP et al. The protective role of DL-alpha-lipoic acid in theoxidative vulnerability triggered by Abeta-amyloid vaccination in mice. MolCell Biochem. 270, 1-2:29-37, 2005.

32. Cho YS et al. alpha-Lipoic acid inhibits airway inflammation andhyperresponsiveness in a mouse model of asthma. J Allergy Clin Immunol.114, 2:429-35, 2004. http://www.sciencedirect.com/science/journal/00916749

33. Venkatraman MS et al. Alpha-Lipoic acid-based PPARgamma agonists fortreating inflammatory skin diseases. Arch Dermatol Res. 296, 3:97-104,2004. http://www.springerlink.com/link.asp?id=100398

34. Jang WG et al. Analysis of proteome and transcriptome of tumornecrosis factor alpha stimulated vascular smooth muscle cells with or withoutalpha lipoic acid. Proteomics. 4, 11:3383-93, 2004. http://www3.interscience.wiley.com/cgi-bin/jhome/76510741

35. Kiemer AK et al. Inhibition of LPS-induced nitric oxide and TNF-alphaproduction by alpha-lipoic acid in rat Kupffer cells and in RAW 264.7 murinemacrophages. Immunol Cell Biol. 80, 6:550-7, 2002. http://www.blackwell-synergy.com/loi/icb

36. Mantovani G et al. Reactive oxygen species, antioxidant mechanisms,and serum cytokine levels in cancer patients: impact of an antioxidanttreatment. J Environ Pathol Toxicol Oncol. 22, 1:17-28, 2003.

37. Bulger EM, Maier RV. "An argument for vitamin E supplementation inthe management of systemic inflammatory response syndrome." Shock.19, 2:99-103, 2003. www.shocksocieties.org/international/shockjournal/

38. Jiang Q, Ames BN. "Gamma-tocopherol, but not alpha-tocopherol,decreases proinflammatory eicosanoids and inflammation damage in rats." FASEBJ. 17, 8:816-22, 2003. www.fasebj.org

39. Wang XL et al. "Cosupplementation with vitamin E and coenzyme Q10reduces circulating markers of inflammation in baboons." Am J Clin Nutr.80, 3:649-55, 2004. www.ajcn.org

40. O'Leary KA et al. "Effect of flavonoids and vitamin E oncyclooxygenase-2 (COX-2) transcription." Mut Res. 551, 1-2:245-54,2004. www.mutationresearch.com

41. Keinan E et al. Natural ozone scavenger prevents asthma in sensitizedrats. Bioorg Med Chem. 13, 2:557-62, 2005.

42. Delaney B et al. Immunotoxicity of a standardized citruspolymethoxylated flavone extract. Food Chem Toxicol. 39, 11:1087-94,2001. http://www.sciencedirect.com/science/journal/02786915

43. Burnett B. A Combination Free-B-Ring Flavonoids and Flavan,Anti-Inflammatory Plant Extract Increases Memory and Speed of Processing inAnimal and Human Clinical Models Presented at 12th Annual Conference onPolyphenols, Helsinki, Finland, August 2004.

44. Chainani-Wu N. "Safety and anti-inflammatory activity of curcumin: acomponent of turmeric (Curcuma longa)." J Altern Comp Med. 9,1:161-8, 2003. www.liebertpub.com

45. Surh YJ et al. "Molecular mechanisms underlying chemopreventiveactivities of anti-inflammatory phytochemicals: down-regulation of COX-2 andiNOS through suppression of NF-kappaB activation." Mut Res.480-481:243-68, 2001. www.mutationresearch.com

46. Yang F et al. Curcumin inhibits formation of amyloid beta oligomersand fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem.280, 7:5892-901, 2005. www.jbc.org

47. Chuang SE et al. "Inhibition by curcumin ofdiethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular geneproducts and cell-cycle-related proteins in rats." Food Chem Tox.38, 11:991-5, 2000. www.elsevier.nl/locate/foodchemtox

48. Surh YJ et al. "Anti-tumor-promoting activities of selected pungentphenolic substances present in ginger." J Environ Pathol Toxicol Oncol.18, 2:131-9, 1999.

49. Frondoza CG et al. "An in vitro screening assay for inhibitors ofproinflammatory mediators in herbal extracts using human synoviocytecultures." In Vitro Cell Dev Biol Anim. 40, 3-4,:95-101, 2004.

50. Bito T et al. Pine bark extract pycnogenol downregulatesIFN-gamma-induced adhesion of T cells to human keratinocytes by inhibitinginducible ICAM-1 expression. Free Rad Biol Med. 28, 2:219-27, 2000. www.elsevier.com/locate/freeradbiomed

51. Lau B et al. Pycnogenol as an adjunct in the management of childhoodasthma. J Asthma. 41, 8:825-32, 2004.

52. Ammon HP. [Boswellic acids , components of frankincense) as the activeprinciple in treatment of chronic inflammatory diseases] Wien MedWochenschr. 152:373-8, 2002.

53. Roy S et al. Human Genome Screen to Identify the Genetic Basis of theAnti-inflammatory Effects of Boswellia in Microvascular Endothelial Cells. DNACell Biol. 24, 4:244-55, 2005.

54. Burgos RA et al. Andrographolide inhibits IFN-gamma and IL-2 cytokineproduction and protects against cell apoptosis. Planta Med. 71,5:429-34, 2005.

55. Langmead L, Makins RJ, Rampton DS. "Anti-inflammatory effects ofaloe vera gel in human colorectal mucosa in vitro." Aliment PharmacolTher. 19, 5:521-7, 2004.

56. Mantle D et al. Adverse and beneficial effects of plant extracts onskin and skin disorders. Adverse Drug React Toxicol Rev. 20, 2:89-103,2001.

57. Kwok BH et al. The anti-inflammatory natural product parthenolide fromthe medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. ChemBiol. 8, 8:759-66, 2001. http://www.sciencedirect.com/science/journal/10745521

58. Li-Weber M et al. The anti-inflammatory sesquiterpene lactoneparthenolide suppresses IL-4 gene expression in peripheral blood T. Eur JImmunol. 32, 12:3587-97, 2002.

59. Zhang S et al. Suppressed NF-kappaB and sustained JNK activationcontribute to the sensitization effect of parthenolide to TNF-alpha-inducedapoptosis in human cancer cells. Carcinogenesis. 25, 11:2191-9, 2004. http://carcin.oujournals.org

60. Smolinksi AT and Pestka JJ. Comparative Effects of the HerbalConstituent Parthenolide (Feverfew) on Lipopolysaccharide-Induced InflammatoryGene Expression in Murine Spleen and Liver. J Inflamm (Lond). 2, 1:6,2005. http://www.journal-inflammation.com/content/2/1/6

61. Lemay M et al. "In vitro and ex vivo cyclooxygenase inhibition by ahops extract." Asia Pac J Clin Nutr. 13, Suppl:S110, 2004.

62. Mizushina Y et al. Structural analysis of catechin derivatives asmammalian DNA polymerase inhibitors. Biochem Biophys Res Commun. 333,1:101-9, 2005. http://www.sciencedirect.com/science/journal/0006291X

63. Di Paola R et al. Green tea polyphenol extract attenuates lung injuryin experimental model of carrageenan-induced pleurisy in mice. Respir Res.6, 1:66, 2005. http://respiratory-research.com/content/6/1/66

64. Macho A et al. Non-pungent capsaicinoids from sweet pepper synthesisand evaluation of the chemopreventive and anticancer potential. Eur JNutr. 42, 1:2-9, 2003. http://www.springerlink.com/link.asp?id=103683

65. Sancho R et al. Immunosuppressive activity of capsaicinoids: capsiatederived from sweet peppers inhibits NF-kappaB activation and is a potentantiinflammatory compound in vivo. Eur J Immunol. 32, 6:1753-63, 2002.http://www3.interscience.wiley.com/cgi-bin/jhome/25061

66. Fiebich BL et al. "Inhibition of TNF-alpha synthesis inLPS-stimulated primary human monocytes by Harpagophytum extract SteiHap69." Phytomedicine. 8, 1:28-30, 2001. www.urbanfischer.de/journals/frame_template.htm?/journals/phytomed/phytmed.htm

67. Zhang XJ et al. Anti-inflammatory actions of cats claw: the role ofNF-kappaB. Aliment Pharmacol Ther. 12, 12:1279-89, 1998.

68. Behnke B et al. Effects of the antirheumatic remedy hox alpha--a newstinging nettle leaf extract--on matrix metalloproteinases in human chondrocytesin vitro. Histol Histopathol. 17, 2:477-85, 2002.

69. Broer J and Behnke B. Immunosuppressant effect of IDS 30, a stingingnettle leaf extract, on myeloid dendritic cells in vitro. J Rheumatol.29, 4:656-8, 2002. www.jrheum.com

70. Qiu D and Kao P. Immunosuppressive and anti-inflammatory mechanisms oftriptolide, the principal active diterpenoid from the Chinese medicinal herbTripterygium wilfordii Hook. f. Drugs R D. 4, 1:1-18, 2003.

71. Presented at First International Congress on Pre-Diabetes and MetabolicSyndrome, Berlin, Germany, April 2005.

72. Thie NM et al. Evaluation of glucosamine sulfate compared to ibuprofenfor the treatment of temporomandibular joint osteoarthritis: a randomized doubleblind controlled 3 month clinical trial. J Rheumatol. 28, 6:1347-55,2001. www.jrheum.com

73. Chou Mm et al. Effects of chondroitin and glucosamine sulfate in adietary bar formulation on inflammation, interleukin-1beta, matrixmetalloprotease-9, and cartilage damage in arthritis. Exp Biol Med(Maywood). 230, 4:255-62, 2005. www.ebmonline.org

74. Hau J et al. Preventive actions of a high dose of glucosamine onadjuvant arthritis in rats. Inflamm Res. 54, 3:127-32, 2005. http://www.springerlink.com/link.asp?id=rl65845j1462661v

75. Meininger CJ et al. Glucosamine inhibits inducible nitric oxidesynthesis. Biochem Biophys Res Commun. 279, 1:234-9, 2004. http://www.sciencedirect.com/science/journal/0006291X

76. Ormrod DJ and Miller TE. A low molecular weight component derived fromthe milk of hyperimmunized cows suppresses inflammation by inhibiting neutrophilemigration. Agents Action. 37, 1-2:70-9, 1992.

77. Colker CM et al. Effects of a milk-based bioactive micronutrientbeverage on pain symptoms and activity of adults with osteoarthritis: adouble-blind, placebo controlled clinical evaluation. Nutr. 18,5:388-92, 2002.

78. Karatay S et al. Effects of different hyaluronic acid products onsynovial fluid levels of intercellular adhesion molecule-1 and vascular celladhesion molecule-1 in knee osteoarthritis. Ann Clin Lab Sci. 34,3:330-5, 2004.

79. Schauss A et al. Presented at Experimental Biology Conference, Federationof American Societies for Experimental Biology, Washington D.C., 2004.

80. Bagchi D et al. Effects of orally administered undenatured type IIcollagen against arthritic inflammatory diseases:a mechanistic exploration. IntJ Clin Pharmacol Res. 22:101-10, 2002.

81. Ausar SF et al. Treatment of rheumatoid arthritis by oraladministration of bovine tracheal type II collagen. Rheumatol Int. 20,4:138-44, 2001.

82. Najm WI et al. S-adenosyl methionine (SAMe) versus celecoxib for thetreatment of osteoarthritis symptoms: a double-blind cross-over trial. BMCMusculoskelet Disord. 5, 1:6, 2004. www.biomedcentral.com

83. Ebisuzaki K. Aspirin and methylsulfonylmethane (MSM): a search forcommon mechanisms, with implications for cancer prevention. AnticancerRes. 23, 1A:453-8, 2003.

84. Anikina NV et al. [The effect of dimethyl sulfoxide on thethromboelastographic indices and the microcirculation in patients with rheumaticdiseases] Ter Arkh. 61, 12:106-9, 1989.

85. Kraemer WJ et al. A cetylated fatty acid topical cream with mentholreduces pain and improves functional performance in individuals with arthritis.J Strength Cond Res. 19, 2:475-80, 2005.

86. Hesslink R et al. Cetylated fatty acids improve knee function inpatients with osteoarthritis. J Rheumatol. 29, 8:1708-12, 2002.

87. Miller MJ et al. Suppression of human cartilage degradation andchondrocyte activation by a unique mineral supplement (SierraSil) and a catsclaw extract, Vincaria. JANA. 7, 2:32, 2004.

88. Maier JA. "Low magnesium and atherosclerosis: an evidence-basedlink." Mol Aspects Med. 24, 1-3:137-46, 2003.

89. Maier JA et al. "Low magnesium promotes endothelial celldysfunction: implications for atherosclerosis, inflammation andthrombosis." Biochim Biophys Acta. 1689, 1:13-21, 2004. www.elsevier.nl/locate/bba

90. Durlach J et al. magnesium depletion with hypo- or hyper-function ofthe biological clock may be involved in chronopathological forms of asthma. MagnesRes. 18, 1:19-34, 2005.

91. Kramer JH et al. Dietary magnesium intake influences circulatingpro-inflammatory neuropeptide levels and loss of myocardial tolerance topostischemic stress. Exp Biol Med. (Maywood). 228, 6:665-73, 2003. www.ebmonline.org

92. Song Y et al. Magnesium intake, C-reactive protein, and the prevalenceof metabolic syndrome in middle-aged and older U.S. women. Diabetes Care.28, 6:1438-44, 2005. http://care.diabetesjournals.org

93. Kind DE et al. Dietary Magnesium and C-reactive protein levels. JAm Coll Nutr. 24, 3:166-71, 2005. www.jacn.org

94. Rahman MJ et al. Effects of zinc supplementation as adjunct therapy onthe systemic immune responses in shigellosis. Am J Clin Nutr. 81,2:495-502, 2005. www.jacn.org

95. Tran CD et al. Short-term zinc supplementation attenuates Helicobacterfelis-induced gastritis in the mouse. J Infect. 50, 5:417-24, 2005. http://www.sciencedirect.com/science/journal/01634453

96. Cui L et al. The permissive effect of zinc deficiency on uroguanylinand inducible nitric oxide synthase gene upregulation in rat intestine inducedby interleukin 1alpha is rapidly reversed by zinc repletion. J Nutr.133, 1:51-6, 2003. www.nutrition.org

97. Kiziltunc A et al. Carnitine and antioxidants levels in patients withrheumatoid arthritis. Scand J Rheumatol. 27, 6:441-5, 1998.

98. Muth CM et al. Influence of an orally effective SOD on hyperbaricoxygen-related cell damage. Free Radic Res. 38, 9:927-32, 2004.

99. Leverdet C et al. GliSODin and Exposure to the sun. France, March2005.

100. Yasui K et al. Superoxide dismutase (SOD) as a potential inhibitorymediator of inflammation via neutrophil apoptosis. Free Radic Res. 39,7:755-62, 2005.

101. Kamenicek V, Holan P, Franek P. "[Systemic enzyme therapy in thetreatment and prevention of post-traumatic and postoperative swelling.]" ActaChir Orthop Traumatol Cech. 68, 1:45-9, 2001.

102. Hale LP. "Proteolytic activity and immunogenicity of oral bromelainwithin the gastrointestinal tract of mice." Int Immunopharmacol. 4,2:255-64, 2004. www.elsevier.com/locate/intimp

103. Gaspani L et al. "In vivo and in vitro effects of bromelain onPGE(2) and SP concentrations in the inflammatory exudate in rats." Pharmacology.65, 2:83-6, 2002.

104. Hale LP et al. Treatment with oral bromelain decreases colonicinflammation in the IL-10-deficient murine model of inflammatory bowel disease.Clin Immunol. 116, 2:135-42, 2005.

105. Rovenska E et al. "Inhibitory effect of enzyme therapy andcombination therapy with cyclosporine A on collagen-induced arthritis." ClinExp Rheumatol. 19, 3:303-9, 2001. www.clinexprheumatol.org

106. Petrof EO et al. "Probiotics inhibit nuclear factor-kappaB andinduce heat shock proteins in colonic epithelial cells through proteasomeinhibition." Gastroenterology. 127, 5:1474-87, 2004. www.gastrojournal.org

107. Lamine F et al. "Colonic responses to Lactobacillus farciministreatment in trinitrobenzene sulphonic acid-induced colitis in rats." ScandJ Gastroenterol. 39, 12:1250-8, 2004. www.tandf.co.uk/journals/titles/00365521.html

108. Pena JA et al. "Probiotic Lactobacillus spp. diminish Helicobacterhepaticus-induced inflammatory bowel disease in interleukin-10-deficientmice." Infect Immun. 73, 2:912-20, 2005. http://iai.asm.org

109. Di Caro S et al. Effects of Lactobacillus GG on genes expressionpattern in small bowel mucosa. Dig Liver Dis. 37, 5:320-9, 2005.

110. Laake KO et al. "Outcome of four weeks' intervention withprobiotics on symptoms and endoscopic appearance after surgical reconstructionwith a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis." ScandJ Gastroenterol. 40, 1:43-51, 2005. www.tandf.co.uk/journals/titles/00365521.html

111. Furrie E et al. "Synbiotic therapy (Bifidobacterium longum/Synergy1) initiates resolution of inflammation in patients with active ulcerativecolitis: a randomized controlled pilot trial." Gut. 54, 2:242-9,2005. http://gut.bmjjournals.com

112. Sauter SN et al. Cytokine expression in an ex vivo culture system ofduodenal samples from dogs with chronic enteropathies: Modulation by probioticbacteria. Domest Anim Endocrinol. Epub ahead of print, June 2005. http://www.sciencedirect.com/science/journal/07397240

Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.

You May Also Like